Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review of literature without formal systematic review/meta-analysis methodology
PubMed 40142611 · doi:10.3390/jcm14061805
What was done
A narrative review of studies indexed in PubMed and EMBASE published before December 31, 2024, evaluating adverse events (frequency, risk factors, anatomical sites, and management strategies) associated with low-dose oral minoxidil treatment for any type of alopecia.
What was found
Hypertrichosis was the most frequent adverse event, occurring in approximately 15% of patients (more common in women and at higher doses). Fluid retention occurred in 1.3% to 10% of patients (predominantly women, typically within 1–3 months). Other cardiovascular adverse events (tachycardia, dizziness) occurred in fewer than 5% of cases and were generally mild and transient. Severe events like pericardial effusion were extremely rare and often related to compounding dosage errors. Adverse events typically resolved with dose reduction, diuretics, or sodium restriction without requiring treatment discontinuation.
Why it matters
Provides clinical guidance on the safety profile of low-dose oral minoxidil, helping prescribers anticipate, monitor, and treat common mild adverse events without prematurely stopping therapy.
Limits
As a narrative review, it lacks systematic search methodology, PRISMA reporting, and formal risk-of-bias assessment. The total number of reviewed studies and patient counts are omitted from the abstract, and data are subject to heterogeneous dosing and adverse-event reporting across the underlying literature.
Cited by
- supports Minoxidil functions as a potassium channel opener and when taken orally can cause pericardial effusion, water retention, and electrolyte dysregulation.